RAPT Therapeutics(RAPT)

SOUTH SAN FRANCISCO, CABiotechnology1 H-1B visas (FY2023)

Focus: RAPT Therapeutics is a public biotechnology company focused on immune-targeted cancer therapies and inflammatory disease treatments. Founded in 2015 and headquartered in South San Francisco, the company operates as a mid-cap biotech with a diversified pipeline across oncology and immunology.

Oncology

Profile data last refreshed 1h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About RAPT Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow RAPT Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Early-stage

8 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$2M

Pipeline & Clinical Trials

FLX925

Acute Myeloid Leukemia

PHASE_1

Clinical Trials (1)

NCT02335814First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Help build intelligence for RAPT Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Public company status provides equity liquidity and established governance structure, reducing startup-stage uncertainty
Diversified pipeline across multiple indications (melanoma, AML, atopic dermatitis, food allergy, asthma) reduces single-program dependency risk
Focus on immune-targeted therapies aligns with high-growth oncology and immunology markets with strong clinical validation potential

Watch Out For

Currently zero Phase 3 programs limits near-term regulatory catalysts; no marketed products mean minimal revenue ($2M in FY2023) to support operations
Rapidly burning cash ($101M R&D spend vs. $47M cash position in FY2024) creates 5-6 month runway without additional financing
No active job openings (0 open positions tracked) suggests potential hiring freeze or contraction phase

Generated by Claude from RAPT Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

14C RPT193

Healthy Male Subjects

PHASE_1

Clinical Trials (1)

NCT06087978Study of RPT193 in Healthy Adult Male Subjects

Phase 1

RPT193

Atopic Dermatitis

PHASE_1

Clinical Trials (1)

NCT04271514A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis

Phase 1

FLX475

Advanced Cancer

PHASE_1_2

RPT193

Atopic Dermatitis

PHASE_2

Clinical Trials (1)

NCT05399368An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis

Phase 2

FLX475

Advanced Melanoma

PHASE_2

Clinical Trials (1)

NCT04894994FLX475 in Combination With Ipilimumab in Advanced Melanoma

Phase 2

RPT193

Asthma

PHASE_2

Clinical Trials (1)

NCT05935332Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma

Phase 2

RPT904

Ig-E Mediated Food Allergy

PHASE_2

Clinical Trials (1)

NCT07220811Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2015

Portfolio: 7 clinical trials

Top TAs: Immunology, Oncology, Respiratory

H-1B (2023): 1 approval

SEC Filings: 2 available

Therapeutic Area Focus

Immunology

2 pipeline

Oncology

2 pipeline

Respiratory

1 pipeline

Marketed

Pipeline

Financials (FY2024)

R&D Spend

$101M51%

Net Income

-$117M

Cash

$47M

Source: SEC 10-K Filing

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Private Funding (SEC Form D)

Jun 2022

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo